MedTrace Logo

A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

NCT03246854 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-12-17

No results posted yet for this study

Summary

The study is being performed to assess the MTD, pharmacokinetics (PK), safety, tolerability and preliminary antitumor activity of DBPR112 in patients with head and neck cancer and EGFR mutated lung cancer.

Conditions

Interventions

DRUG

DBPR112

DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.

Sponsors & Collaborators

  • National Health Research Institutes, Taiwan

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-18
Primary Completion
2018-08-04
Completion
2018-08-04
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03246854 on ClinicalTrials.gov